Europe — EMA

Odelniqva (Dapagliflozin)

Dapagliflozin, the active ingredient in Odelniqva, is a SGLT2 inhibitor presented as a unknown/unknown for oral use. It treats type 2 diabetes mellitus in adults.

Dapagliflozin

Request sourcing

Pack/s

What is Dapagliflozin?

Dapagliflozin, the active ingredient in Odelniqva, is a SGLT2 inhibitor presented as a unknown/unknown for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Odelniqva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Odelniqva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Dapagliflozin used for?

Odelniqva is a SGLT2 inhibitor that improves glycaemic control in the following:

- Type 2 diabetes mellitus: Provides the only or additional glucose‑lower effect by increasing urinary glucose excretion. - Heart failure: Reduces the risk of cardiovascular hospitalisation and cardiovascular death in patients with reduced ejection fraction. - Chronic disease of … .... … . - … … .... ... … """"

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →